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Abstract Ullrich congenital muscular dystrophy
(UCMD) is a severe disorder caused, in most cases, by
a deficiency in collagen VI microfibrils. Recessive
mutations in two of the three collagen VI genes,
COL6A2 and COL6A3, have been identified in eight of
the nine UCMD patients reported thus far. A hetero-
zygous COL6A1 gene deletion, resulting in a mutant
protein that exerts a dominant negative effect, has re-
cently been described in a severely affected UCMD
patient. Here we describe a patient in whom reverse
transcription-PCR analysis of fibroblast RNA sug-
gested a heterozygous in-frame deletion of exon 13 in
the triple-helical domain of COL6A2, which is pre-
dicted to be dominantly acting. However, a homozy-
gous A fi G mutation at 10 of intron 12 was found
in the genomic DNA. The intron mutation activated
numerous cryptic splice acceptor sites, generating nor-
mal and exon 13-deleted COL6A2 mRNA, and multi-
ple aberrant transcripts containing frameshifts that
were degraded through a nonsense-mediated decay
mechanism. Northern analysis indicated diminished
COL6A2 mRNA expression as the primary pathogenic
mechanism in this UCMD patient. Our results under-
score the importance of multifaceted analyses in the
accurate molecular diagnosis and interpretation of
genotype-phenotype correlations of UCMD.
Introduction
Ullrich congenital muscular dystrophy (UCMD, MIM
254090) is a severe disorder affecting both muscle and
connective tissue. It is characterized by neonatal muscle
weakness, proximal joint contractures, marked distal
joint hyperlaxity, and normal intelligence (Bertini and
Pepe 2002). Additional clinical features may include
kyphosis, scoliosis, torticollis, rigid spine, and hip dis-
location. Patients affected with UCMD have delayed
motor milestones and may never walk independently.
Respiratory function is often severely compromised,
leading to respiratory failure requiring noninvasive
ventilation from the 1st to 3rd decades of life.
In 2001, UCMD was first shown to result from a
deficiency in collagen VI due to recessive mutations in
COL6A2, one of the three subunit genes encoding the
protein (Camacho Vanegas et al. 2001; Higuchi et al.
2001). Since then, mutations in all three collagen VI
genes have been reported in nine families, eight of
which carry homozygous or compound heterozygous
frameshift, nonsense, or splice junction mutations in
COL6A2 or COL6A3 that result in the absence or se-
vere reduction of collagen VI protein (Demir et al.
2002; Ishikawa et al. 2002). The exception is a severely
affected UCMD patient who carries a de novo het-
erozygous deletion in COL6A1, resulting in an in-frame
deletion in the a1(VI) collagen chain that exerts a
dominant negative effect (Pan et al. 2003). Hence,
UCMD can arise from either recessive or dominant
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negative mutations. Previously, dominant mutations in
all three collagen VI genes have been associated with
the milder Bethlem myopathy, characterized by con-
genital muscle weakness and multiple joint contractures
(Bertini and Pepe 2002).
The a1(VI), a2(VI) and a3(VI) chains of collagen VI
are 140, 140 and 260–300 kDa in size, respectively (see
Timpl and Chu 1994). Each chain contains a central
triple-helical domain of 335–336 amino acids with
repeating Gly-Xaa-Yaa amino acid sequences, which is
flanked by amino- and carboxyl-globular domains. The
three chains are folded, through the triple-helical do-
mains, into collagen VI monomers that are further
assembled into dimers and tetramers prior to secretion
from cells. In the extracellular space, the tetramers are
associated end-to end into the characteristic double-
beaded collagen VI microfibrils. Thus, mutations
affecting the multiple assembly steps can have strong
dominant negative effects, resulting in the total absence
of collagen VI microfibrils (Pan et al. 2003).
Here, we report a UCMD patient showing an appar-
ently heterozygous in-frame deletion in the triple-helical
domain of the a2(VI) collagen chain byRT-PCRanalysis,
as a consequence of a homozygous single nucleotide
substitution in the intron that causes complex aberrant
splicing. This type of mutation mechanism has not been
reported previously in UCMD. Our finding is highly rel-
evant to the accurate molecular diagnosis of the disorder.
Fig. 1 a Immunofluorescence
analysis of muscle biopsies (top
panels) and dermal fibroblasts
(bottom panels) from the control
(Con) and patient (Pat). Muscle
biopsies were immunostained
with a collagen VI monoclonal
antibody (MAB 3303,
Chemicon), followed by a
biotinylated anti-mouse
secondary antibody and
streptavidin–Texas red
conjugate. Fibroblasts were
grown in the presence of 50 lg/
ml L-ascorbic acid phosphate
for 4 days post-confluency and
stained with an a1(VI) collagen
specific antibody. The antibody
reaction was detected with Cy3
conjugated goat anti-rabbit
IgG, showing extensive collagen
VI microfibillar network in the
control fibroblasts and only
cytoplasmic staining in the
patient fibroblasts. Original
magnifications: ·20. b RT-PCR
analysis of total RNA from
fibroblasts using a primer pair
that amplify a 546 bp fragment
in the N-terminal portion of the
triple-helical domain of the
COL6A2 mRNA. Lane 1
control RNA, lane 2 patient
RNA, lane 3 patient RNA from
cells treated with 100 lg/ml
cycloheximide, and lane 4 DNA
size marker
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Materials and methods
Patient
The propositus was a 5-year-old Caucasian male. He
presented at the age of 3 months with hypotonia, bilat-
eral hip dislocation and recurrent chest infections. His
motor milestones were severely delayed: he stood at
31 months but has never achieved independent ambu-
lation. At a recent clinical examination, he showed
generalized muscle weakness, affecting more severely the
proximal muscle in the limbs and distal laxity involving
elbow, fingers, and ankles. Flexion contractures of hips
and knees were also present. He had mild spine rigidity.
Muscle biopsy and dermal fibroblasts established
from skin biopsy were used in this study. The biological
specimen was collected in accordance with the institu-
tional review board-approved human subject protocols.
Mutation detection
Mutation analysis was performed by RT-PCR amplifi-
cation and direct sequencing of the entire coding regions
of all three collagen VI mRNAs using methods and
primers described previously (Camacho Vanegas et al.
2001; Pan et al. 2003). The primers used to identify the
COL6A2 mRNA deletion were forward 5¢-ATCGGA-
CCTCCTGGCTGCAA and reverse 5¢-GGGTCCTG-
GGTAGCTGAATC, which amplified a 546 bp cDNA
fragment. Exon 13 plus its flanking intron sequences in
COL6A2 was PCR amplified from the genomic DNA
using primers 5¢-GACACACACTCTGCCCTCAG
(forward) and 5¢-CTCAAGCTGCAAGGAGGATG
(reverse), which amplified a 758 bp fragment. The PCR
products were directly sequenced.
Immunohistochemical, molecular and biochemical
analyses
Immunohistochemical study of muscle biopsies was
performed by incubating 7 lm cryosections with a col-
lagen VI monoclonal antibody (MAB 3303, 1/400 dilu-
tion, Chemicon), followed by a biotinylated anti-mouse
secondary antibody (Amersham) and strepatavidin-
Texas red conjugate (molecular probes).
Immunofluorescence, RNA and protein analyses of
collagen VI in dermal fibroblasts were carried out as
described previously (Pan et al. 2003). Briefly, confluent
fibroblasts grown in the presence of L-ascorbic acid
phosphate for 4 days were immunolabeled with a poly-
clonal antibody specific for the a1(VI) collagen chain
(Tillet et al. 1994). Northern blot hybridization was
performed using total RNA prepared from confluent
fibroblasts and [32P]dCTP-labeled cDNAs encoding the
three collagen VI chains as probes. To assess aberrant
splicing, fibroblasts were grown in 100 lg/ml cyclohex-
imide (Sigma) overnight prior to total RNA isolation
(Bateman et al. 1999). For immunoprecipitation, fibro-
blasts were labeled overnight with [35S]cysteine, and the
resulting cells and culture medium were precipitated
with a polyclonal antibody specific for the a3(VI) col-
lagen chain (Specks et al. 1992).
Results
Immunohistochemical examination of the muscle
biopsy from the patient showed variation in fiber size,
marked reduction of collagen VI in the basal lamina
surrounding the fibers, and positive staining in the
connective tissue between the fibers and in the peri-
vasuclar regions (Fig. 1a). Immunofluorescence analy-
sis of the patient fibroblasts showed strong
cytoplasmic staining and a complete absence of col-
lagen VI microfibrils in the extracellular matrix. These
observations indicated the presence of a collagen VI
defect in the patient. Therefore, the coding regions of
the three collagen VI mRNAs were RT-PCR amplified
with 25 primer pairs in their entirety, and the resulting
products were analyzed by agarose gel electrophoresis.
A primer pair specific for the triple-helical domain of
the COL6A2 mRNA amplified two cDNA fragments,
the expected 546 bp band and a slightly shorter frag-
ment (Fig. 1b, lane 2). DNA sequencing revealed that
the shorter fragment contained a 63 bp deletion,
corresponding to exon 13 (Fig. 2a). The larger PCR
product showed no deviation from the COL6A2
mRNA reference sequence. The results suggested that
the patient might carry a heterozygous splice junction
mutation causing exon skipping. A number of single
nucleotide changes were also identified by sequencing
the entire coding regions of the three chains, three of
which result in amino acid substitutions in COL6A3
(Table 1). These nucleotide changes have frequently
been observed in Europeans (Lampe et al. 2005), and
Fig. 2 a Top: Schematic diagram of the COL6A2 genomic region
encompassing exons 12–14 (open boxes), which encode the triple-
helical domain (top). A homozygous IVS12-10a fi g mutation is
present in the genomic DNA of the patient. Bottom: Nucleotide
sequence of the corresponding region. Exon sequences are in
capital letters. Potential splice acceptor sites predicted by computer
analysis are depicted by open arrowheads, and filled arrowheads
indicate two sites identified in cDNA clones. Asterisk marks the
intron 12 mutation in the patient. b Northern blot analysis of total
RNA (5 lg) from control and patient fibroblasts using a mixture of
[32P]dCTP-labeled cDNA probes for the three collagen VI mRNA.
The probes hybridized with the COL6A1, COL6A2 and COL6A3
mRNA of 4.2, 3.5 and 9–10 kb, respectively, plus an alternatively
spliced COL6A2 mRNA (COL6A2a) of 6.0 kb. c Immunoprecip-
itation of culture media (left) and cells (right) from control and
patient fibroblasts with the antibody specific for the a3(VI) collagen
chain. Fibroblasts were labeled with [35S]cysteine overnight.
Samples were reduced with 25 mM DTT and separated on a 3–
8% polyacrylamide gel. Note that a strong band migrated at the
position of the a1(VI) collagen chain is seen in the cells from the
patient, whereas equal amounts of the a1(VI) and a2(VI) chains,
which are not completely resolved in this gel, are observed in the
control. In the culture medium, a small amount of fibronectin (FN)
is also precipitated by the antibody
b
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thus are unlikely to be pathogenic. The patient is
heterozygous for a 2667G fi A polymorphism in
COL6A1, suggesting that both COL6A1/COL6A2 al-
leles are present.
The genomic DNA encompassing exons 12–14
(1.2 kb) was next PCR amplified and sequenced.
Unexpectedly, the only sequence change detected was a
homozygous A fi G transition at position 10 of in-
tron 12 (Fig. 2a). His unaffected mother is heterozygous
for this A fi G change. The genomic DNA of his father
was not available for analysis.
Close inspection of the RT-PCR products showed
that the normal and shortened cDNA fragments were
not present in equal quantity, an observation inconsis-
tent with the postulation of a heterozygous splice junc-
tion mutation. Northern blot hybridization was
performed to examine whether the intron mutation re-
sulted in quantitative or qualitative changes in the
COL6A2 mRNA. As shown in Fig. 2b, the COL6A2
mRNA level in the patient was substantially reduced
compared to the normal control, whereas the amounts
of the COL6A1 and COL6A3 mRNAs in the patient
and control were similar. The data suggested that the
majority of the COL6A2 mRNA in the patient fibro-
blasts was degraded, most likely through nonsense-
mediated mRNA decay (Frischmeyer and Dietz 1999).
This possibility was further investigated by RT-PCR
analysis of total RNA prepared from the patient fibro-
blasts that had been treated with cycloheximide to in-
hibit RNA degradation. Several additional cDNA
fragments larger than the normal product of 546 bp
were observed, indicating that aberrant splicing had ta-
ken place (Fig. 1b).
The multiple RT-PCR products were cloned into
the pCRII-TOPO plasmid (Invitrogen). DNA
sequencing of individual clones revealed that at least
two cryptic splice acceptor sites in intron 12 were
utilized (Fig. 2a, filled arrowheads). Both sites con-
tained a short pyrimidine-rich sequence followed by a
consensus splice acceptor site sequence (cag). Both
transcripts were out-of-frame and predicted to result
in premature stop codons, and therefore subject to
nonsense-mediated mRNA decay. A computer search
employing a modification of the algorithm described
by Shapiro and Senapathy (1987) identified numerous
potential splice acceptor sequences of significant
strength within introns 12 and 13 (Table 2). The
strength of the two cryptic splice acceptor sites
identified experimentally was slightly higher than that
of the normal acceptor site in intron 12. Though not
all of the PCR products obtained from cells treated
with cycloheximide were cloned and sequenced, it is
conceivable that these products resulted from utiliza-
tion of different cryptic splice acceptor sites in the
intron.
The consequence of the mutation at the protein level
was studied by immunoprecipitation of metabolically
labeled fibroblasts. An antibody specific for the a3(VI)
collagen chain was used so that only those a1(VI) and
a2(VI) collagen chains that are associated with the
a3(VI) chains would be coimmunoprecipitated. The
analysis showed markedly reduced amounts of collagen
VI protein in the culture medium from the patient fi-
broblasts as compared to the control fibroblasts
(Fig. 2c). Cells from the patient revealed a strong band
that migrated at the position of the a1(VI) collagen, in
contrast to a broad band corresponding to equal
amounts of the partially resolved a1(VI) and a2(VI)
chains found in the control. The a2(VI) chain normally
migrates somewhat more slowly than the a1(VI) chain
under this gel separation condition (Pan et al. 2003).
Together, the results suggest that the small amount of
the normal a2(VI) chains produced by the patient’s
fibroblasts were rapidly assembled and secreted extra-
cellularly. The strong band in the cells from the patient
might consist of both the normal a1(VI) chain and the
Table 1 Nucleotide changes in collagen VI genes
Gene Exon Nucleotide change Amino acid change Status Polymorphism
frequencya
COL6A1 35 2549G fi A R850H Homozygous 37/108 chromosomes
COL6A1 35 2667G fi A A889A Heterozygous 39/110 chromosomes
COL6A1 35 2796C fi T S932S Homozygous 40/112 chromosomes
COL6A2 26 2094G fi A A698A Homozygous 68/154 chromosomes
COL6A2 26 2097C fi T G699G Homozygous 68/154 chromosomes
COL6A2 26 2184G fi A V728V Homozygous 61/154 chromosomes
COL6A2 28 2697T fi G T889T Homozygous 4/150 chromosomes
COL6A3 28 6855G fi C G2285G Heterozygous 77/158 chromosomes
COL6A3 36 7596G fi A K2532K Heterozygous 17/156 chromosomes
COL6A3 39 8491G fi C D2831H Heterozygous 15/156 chromosomes
COL6A3 40 8780C fi T T2927M Heterozygous 66/154 chromosomes
COL6A3 40 8820A fi G T2940T Homozygous 12/156 chromosomes
COL6A3 40 9031C fi G P3011A Heterozygous 42/156 chromosomes
The reference sequences for the three collagen VI mRNAs are NM_001848 for COL6A1, NM_001849 for COL6A2, and NM_004369 for
COL6A3 (NCBI database). Nucleotide positions are numbered based on +1 being the A of the translation start codon
aData from Lampe et al. (2005)
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mutant a2(VI) chain containing the internal exon 13
deletion of 21 amino acids.
Discussion
By mutation, mRNA, and protein analyses, we dem-
onstrate that a homozygous mutation at position 10
in intron 12 of COL6A2 can cause UCMD. Nucleotide
position 10 of splice acceptor sites is not strictly
conserved. Although C and T are the preferred nucle-
otides for this position, A and G are each found
approximately 10% of the time in human genes (Zhang
1998). Hence, the A fi G change detected in the
genomic DNA normally would not be considered
pathogenic. On the other hand, computer analysis
indicates that the strength of the splice acceptor site of
intron 12 is relatively weak (score 83.5) compared to
those of introns 11, 13, and 14 (scores 91.0–93.5), and
that introns 12 and 13 contain several potential alter-
native splice acceptor sites with a strength comparable
to the normal splice acceptor site (Table 2). It is con-
ceivable that the single base change at 10 disrupts the
relatively weak interaction of the intron 12 acceptor
site and the splicing machinery, resulting in the acti-
vation of the cryptic splice acceptor sites. Most of the
aberrant transcripts are degraded by the nonsense-
mediated decay mechanism as evidenced by northern
analysis, whereas the correctly spliced COL6A2 mRNA
and the transcript with an in-frame deletion of exon 13
remain intact. If mutation screening had been per-
formed by RT-PCR analysis of the mRNA alone,
detection of normal and exon 13-deleted COL6A3
mRNA would be misinterpreted as resulting from a
heterozygous splice junction mutation.
The mutant a2(VI) collagen chain contains a small
in-frame deletion in the N-terminus of the triple-helical
domain, so it is most likely able to incorporate into a
triple-helical monomer (Pan et al. 2003). It also pre-
serves the key cysteine residue needed for maintaining
the stability of dimers, and therefore the mutant
monomer is predicted to undergo dimer and tetramer
formation and be secreted. With a misaligned
N-terminal triple-helical region, the abnormal tetramer
likely will exert a dominant negative effect on the end-to-
end assembly into microfibrils. Indeed, though the bio-
synthetic study indicates that some collagen VI tetra-
mers are secreted extracellularly, few collagen VI
microfibrils can be detected by immunofluorescence,
consistent with the notion that the mutant tetramers
interfere with microfibrillar formation. Because most of
the abnormal transcripts are degraded and only a small
amount of the mutant chain is produced, the mutation
most likely will not have a striking dominant effect in the
heterozygous condition. Indeed, the patient’s mother,
who is a heterozygous carrier of the mutation, does not
display any clinical abnormality.
Predicting splice defects based on sequencing geno-
mic DNA is rather difficult. Moreover, missense changes
in exons also may disrupt exon enhancer sequences,
thereby causing defects in splicing. Our study demon-
strates that in order to understand the precise mecha-
nism of a mutation, both quantitative and qualitative
analyses of the mRNA are necessary. The unconven-
tional splicing defect described here presents a challenge
to the molecular diagnosis of UCMD, which is already
fairly complex because of the possibility of either
recessive or dominant mutations. The results highlight
the importance of combined molecular and functional
analyses in accurate interpretation of genotype-pheno-
type correlations, a prerequisite for the development of
therapeutic strategies.
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Table 2 Potential splice acceptor sites in introns 12 and 13 of
COL6A2
Nucleotide
positiona
Potential splice
acceptor sequenceb
Scorec Comment
283–297 cgctgctcaccgag|g 73.8
312–326 ccacctcctcccag|g 91.0
318–332 cctcccaggtggag|c 66.4
376–390 cgttggtgccccag|g 84.5
498–512 ccaccttccctcag|c 83.6 Site used in 2
cDNA clones
504–518 tccctcagcccaag|c 71.6
529–543 ctgagtcctctgag|c 71.0
532–546 agtcctctgagcag|a 80.2
540–564 gagcagatgcacag|g 68.1
573–597 cactctgccctcag|c 84.1
594–608 ggaggttccagcag|c 67.8
601–615 ccagcagcccccag|c 72.2
605–619 cagcccccagccag|c 72.8
681–695 tcctgcccccgcag|c 86.4 Site used in 2
cDNA clones
745–759 gcaaacccttccag|G 83.5 Intron 12
acceptor site
764–778 CCCTGGCCGCCCAG|G 85.0
836–850 ctcttcgcctgcag|c 87.7
868–882 cgcccatggcccag|a 74.8
1004–1018 gccctcctcacgag|g 77.1
1020–1034 tgaacaagttccag|c 74.2
1032–1046 aggggaccctgcag|g 74.2
1101–1115 cacacaccgcacag|c 78.6
1161–1175 Ctctccttcttcag|G 93.5 Intron 13
acceptor site
1277–1291 tgcccctgcctcag|c 88.3
a Nucleotide sequence of the genomic region analyzed is shown in
Fig. 2a
b Potential splice acceptor sites analyzed using the computer pro-
gram at http://www.genet.sickkids.on.ca/ali/splicesitefinder.html,
which employs an algorithm modified from Shapiro and Senapathy
(1987). Intron sequences are shown in lower case letters, and exon
sequences in capital letters. Vertical lines mark intron/exon
boarders
c Strength of the splice acceptor sites calculated using the above
computer program
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